EcoPro BM Co., Ltd. (247540.KQ), a South Korean manufacturer of cathode materials used in batteries, Thursday reported lower operating income on lower revenue for the third quarter compared to the same period last year.
Quarterly operating income dropped 76.2 percent to KRW 12.02 billion from KRW 50.48 billion last year.
Revenue decreased to KRW 557.92 billion from KRW 625.06 billion previous year.
Currently, shares are trading at KRW 91,100, down 6.28% on the Korean Stock Exchange.
For comments and feedback contact: [email protected]
Business News
November 03, 2026 10:34 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.